Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - olanzapine, quantity: 2.5 mg - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; hyprolose; microcrystalline cellulose; lactose monohydrate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - treatment of schizophrenia and related psychoses. short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder. preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - risperidone, quantity: 3 mg - tablet, film coated - excipient ingredients: lactose monohydrate; sodium lauryl sulfate; microcrystalline cellulose; pregelatinised maize starch; magnesium stearate; colloidal anhydrous silica; titanium dioxide; hypromellose; propylene glycol; purified talc; quinoline yellow aluminium lake - rixadone is indicated for,- the treatment of schizophrenia and related psychoses.,- the short term treatment of acute mania associated with bipolar 1 disorder (see dosage and administration: bipolar mania).,- the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. (see dosage and administration: behavioural disturbances in dementia).,- the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data).,- the treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - risperidone, quantity: 4 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; lactose monohydrate; sodium lauryl sulfate; pregelatinised maize starch; colloidal anhydrous silica; titanium dioxide; hypromellose; propylene glycol; purified talc; quinoline yellow aluminium lake; indigo carmine aluminium lake - rixadone is indicated for,- the treatment of schizophrenia and related psychoses.,- the short term treatment of acute mania associated with bipolar 1 disorder (see dosage and administration: bipolar mania).,- the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. (see dosage and administration: behavioural disturbances in dementia).,- the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data).,- the treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - risperidone, quantity: 2 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; sodium lauryl sulfate; colloidal anhydrous silica; lactose monohydrate; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; propylene glycol; sunset yellow fcf aluminium lake; purified talc - rixadone is indicated for,- the treatment of schizophrenia and related psychoses.,- the short term treatment of acute mania associated with bipolar 1 disorder (see dosage and administration: bipolar mania).,- the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. (see dosage and administration: behavioural disturbances in dementia).,- the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data).,- the treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - risperidone, quantity: 0.5 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; lactose monohydrate; pregelatinised maize starch; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; propylene glycol; purified talc; iron oxide red; iron oxide black - rixadone is indicated for - the treatment of schizophrenia and related psychoses.,- the short term treatment of acute mania associated with bipolar 1 disorder (see dosage and administration: bipolar mania).,-the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. (see dosage and administration: behavioural disturbances in dementia).,- the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data).,- the treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - risperidone, quantity: 1 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; microcrystalline cellulose; colloidal anhydrous silica; lactose monohydrate; pregelatinised maize starch; magnesium stearate; titanium dioxide; hypromellose; propylene glycol; purified talc - rixadone is indicated for,- the treatment of schizophrenia and related psychoses.,- the short term treatment of acute mania associated with bipolar 1 disorder (see dosage and administration: bipolar mania).,- the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. (see dosage and administration: behavioural disturbances in dementia).,- the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data).,- the treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - bisoprolol fumarate, quantity: 10 mg - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; pregelatinised maize starch; croscarmellose sodium; iron oxide yellow; iron oxide red; macrogol 4000; titanium dioxide; hypromellose; lactose monohydrate - treatment of stable chronic moderate to severe heart failure in addition to ace inhibitors, and diuretics, and optionally cardiac glycosides.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - bisoprolol fumarate, quantity: 5 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; croscarmellose sodium; iron oxide yellow; calcium hydrogen phosphate; colloidal anhydrous silica; pregelatinised maize starch; hypromellose; lactose monohydrate; macrogol 4000; titanium dioxide - treatment of stable chronic moderate to severe heart failure in addition to ace inhibitors, and diuretics, and optionally cardiac glycosides.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - bisoprolol fumarate, quantity: 2.5 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; pregelatinised maize starch; microcrystalline cellulose; calcium hydrogen phosphate; colloidal anhydrous silica; magnesium stearate; hypromellose; titanium dioxide; macrogol 4000; lactose monohydrate - treatment of stable chronic moderate to severe heart failure in addition to ace inhibitors, and diuretics, and optionally cardiac glycosides.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - olanzapine, quantity: 15 mg - tablet, film coated - excipient ingredients: magnesium stearate; hyprolose; lactose monohydrate; microcrystalline cellulose; hypromellose; crospovidone; titanium dioxide; polysorbate 80; macrogol 400; indigo carmine aluminium lake - olanzapine tablets are indicated for the treatment of schizophrenia and related psychoses.,olanzapine tablets alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.,olanzapine tablets are also indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.